MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1

In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanced NSCLC with topics including:

• Incorporating MET exon 14 testing into standard of care
• Comparison of RNA-based and DNA-based NGS platforms
• Availability of RNA-based NGS testing around the world
• Using FISH to quantify MET copy gain/amplification
• Regulatory and clinical differences between new, selective MET inhibitors
• Safety profiles of type I vs type II MET inhibitors
• Counseling patients on management of peripheral edema, a class effect with MET inhibitor therapy
• Insights on combining MET inhibition with immune checkpoint inhibition therapy or chemotherapy
• Selecting second-line therapy for a patient with MET exon 14–altered NSCLC progressing on tepotinib or capmatinib

Presenters:
Luis Paz-Ares, MD, PhD
Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

Karen L. Reckamp, MD, MS
Professor of Medicine
Director, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Content based on an online CME program supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

Link to full program, including associated downloadable slidesets:
https://bit.ly/2ExadCf

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.